Abstract: Genetic risk factors could cause cutaneous adverse drug reactions (cADRs) in patients after treatment with clarithromycin. This study explored the association of HLA class I genes with clarithromycin-cADRs in Han Chinese patients. A total of 12 clarithromycin-cADR patients and 34 clarithromycin-tolerant controls were recruited for the high-resolution genotyping of HLA class I genes (HLA-A, HLA-B and HLA-C). The population controls consisted of 283 Han Chinese retrieved from the MHC database for validated comparison. A molecular docking analysis of HLA-A*02:07 protein and clarithromycin was conducted using glide module with Schr€ odinger Suite. Among all tested HLA alleles, the carrier frequencies of HLA-A*02:07 (58% versus 5.9%, OR = 22.40, 95% CI = 3.58-139.98, p = 8.20 9 10E-5, pc = 1.1 9 10E-3) and HLA-B*46:01 (50% versus 5.9%, OR = 16.00, 95% CI = 2.59-98.99, p = 0.002, pc = 0.03) were significantly higher in clarithromycin-cADRs than in clarithromycin-tolerant controls. However, when compared to population controls, only HLA-A*02:07, and not HLA-B*46:01, reached statistical significance (58% versus 15.5%, OR = 7.61, 95% CI = 2.31-25.04, p = 1.2 9 10E-4, pc = 1.7 9 10E-3). Furthermore, molecular docking data revealed that clarithromycin could bind to and interact with HLA-A*02:07 in two possible binding situations. These data suggest that HLA-A*02:07 might be a genetic risk factor for developing clarithromycin-cADRs in Han Chinese and serve as a useful biomarker for personalized medicine to prevent clarithromycin-cADRs.
Clarithromycin (6-O-methyl erythromycin) is a frequently prescribed macrolide antibiotic to treat various bacterial infections in clinic, including mild to moderate bacterial infections caused by susceptible isolates of Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis or Streptococcus pneumoniae, such as acute or chronic bronchitis, acute maxillary sinusitis or otitis media, duodenal ulcer disease, community-acquired pneumonia or other unusual skin infections [1, 2] . Clarithromycin was initially developed in 1980 and is presently recommended by the World Health Organization as an essential medicine due to its clinical effectiveness and safety record [3] . Clarithromycin has also been recommended for use in combination with proton pump inhibitors (PPI) or ranitidine bismuth citrate (RBC) plus other two antibiotics (amoxicillin or metronidazole) to treat Helicobacter pylori infection, and the latter infection frequently results in the development of peptic ulceration or stomach cancer [4, 5] .
However, clarithromycin does possess some common side effects, such as cough, fever, chills, hoarseness, back pain, urination problems and several adverse reactions such as stomach tenderness, nausea, vomiting, bleeding, bruising, watery, diarrhoea and other cutaneous problems [3] [4] [5] . The common adverse effects of clarithromycin are clarithromycin-induced cutaneous adverse drug reactions (cADRs), which manifest symptoms of urticaria, mild skin eruptions, Stevens-Johnson syndrome and toxic epidermal necrolysis, and have a high prevalence within the first 6 weeks of medication [3] [4] [5] . cADRs are unpredictable reactions to a drug that often necessitate treatment withdrawal. Previous studies have provided evidence that some specific human leucocyte antigen (HLA) alleles, especially HLA class I genes, are strongly associated with cADRs [6] [7] [8] , such as HLA-A*31:01, HLA-B*13:02 and HLA-B*15:01 alleles [9] [10] [11] , and these have been used as clinical markers to predict relevant cADRs. The progress of pharmacogenetics has provided in-depth insights into an individual's susceptibility to cADRs and represents an important milestone towards stratified/precision medicine. However, few studies have reported on the contributions of HLA genetic variants and their association with clarithromycin-cADRs. In this study, we aimed to investigate the association between HLA class I genes and clarithromycin-cADRs in Chinese patients and molecularly mould the possible clarithromycin binding to HLA-A protein, in order to characterize their interaction.
University (Shanghai, China) between September 2014 and August 2016. cADR diagnosis was independently assessed by two experienced dermatologists according to the medical history and histological and laboratory tests of each patient. Histology and serum tests were used to exclude viral infections and other diseases. The cADR criteria led the investigators to diagnose these patients into three types: urticarial plaques that lasted for more than 24 hr, erythema multiforme (EM) with typical or oedematous red papules and one or more mucous membranes and maculopapular eruption (MPE). In addition, patients who have been prescribed and treated with clarithromycin (500 mg bid alone) without developing any adverse reaction in more than 3 months were recruited into this study as clarithromycin-tolerant controls and were evaluated for genetic risk factors. The protocol of this study was approved by the Ethics Committee of Fudan University, and a written informed consent was obtained from each patient prior to enrolment into the study.
Tissue samples and genotyping. For each patient, 4.0 ml of venous blood was collected, placed into ethylenediaminetetra-acetic acid (EDTA) tubes and stored at À20°C until use. The genomic DNA was prepared from venous blood using an AxyPrep TM Blood Genomic DNA Miniprep Kit (Axygen Biotechnology, Union City, CA, USA). After quantification, these genomic DNA samples were subjected to a high-resolution HLA genotyping procedure performed by Mentality Bio-Tech Co. Ltd. (Beijing, China) using polymerase chain reactionsequence-specific oligonucleotide (PCR-SSO) with the LABT â SSO kit (One Lambda, Canoga Park, CA, USA) for HLA-A, HLA-B and HLA-C. Then, the DNA sequence data were analysed using HLAFusion software version 3.0 (One Lambda). In particular, small molecules were first processed using LigPrep version 2.5 (Schrodinger, Inc.) to produce the corresponding lowenergy three-dimensional structures and the correct ionization state (pH = 7.0). Then, hydrogen atoms and protein charges were added during a brief relaxation period of time. The receptor grid file was generated using an enclosing box centred on potential pockets predicted earlier by F pocket (http://fpocket.sourceforge.net/). The maximum length of the ligand to be docked was set to 25 A to define an appropriate box size. The processed small molecules were subsequently docked into the assumed binding pocket of PAFR with the Glide-SP (standard-precision) mode, outputting the top 10 conformations, respectively. A default setting was used for refinement and scoring. Then, the most reliable binding poses were selected according to the favourable interaction energy and visual inspection, based on previous studies [12, 13] .
Results

Characteristics of patients.
In this study, 12 patients with clarithromycin-induced cADRs were recruited and genotyped, including five male (41.7%) and seven female (58.3%) patients, and the mean age of these patients was 46.16 years old (range: 23-67 years old; table 1). In addition, 34 clarithromycin-tolerant subjects with similar gender and age distributions were also included (data not shown). Patients with clarithromycininduced cADRs were independently diagnosed by two experienced dermatologists. Among these patients, seven (58.3%) patients had urticarial plaques that lasted for more than 24 hr, three (25.0%) patients had erythema multiforme (EM), who had typical or oedematous red papules that involved one or more mucous membranes, and two (16.7%) patients had maculopapular exanthems (MPE). Among the seven patients with urticaria, three patients had an allergic history of sulphonamides, penicillin or cephalosporins, respectively, while the remaining five patients did not show any history of allergy. These significant associations were further validated between alleles and cADRs in another independent cohort of 283 healthy southern Han Chinese subjects from the general population (retrieved from the MHC database, http://www.ncbi.nlm.nih.gov/ mhc) (table 3) . Specifically, for HLA-B*46:01, there was no significant difference in allele or genotype frequencies between cADR patients and controls, but the HLA-A*02:07 frequency was significantly higher (58.0%, 7/12) in cADR patients than that in the population of controls (15.5%, 44/283, OR = 7.61, 95% CI = 2.31-25.04, p = 1.2 9 10E-4, pc = 1.7 9 10E-3).
Molecular moulding of clarithromycin binding to HLA-A*02:07. Next, the association between HLA-A*02:07 and clarithromycin was investigated using in silico docking analysis. As shown in fig. 1A , clarithromycin could bind to and interact with HLA-A*02:07 for three possible binding sites, including 
Discussion
In the present study, HLA-A, HLA-B and HLA-C were genotyped for 12 clarithromycin-induced cADR patients and 34
clarithromycin-tolerant patients, and the data were analysed against the HLA allele frequency data on 283 healthy controls of Han Chinese subjects obtained from the MHC database. It was found that, among these 12 patients, seven (58.3%) patients suffered from urticarial plaques that lasted for more than 24 hr, three (25.0%) patients suffered from EM with typical or oedematous red papules and one or more mucous membranes, and two (16.7%) patients suffered from maculopapular eruption. The frequency of the HLA-A*02:07 allele was significantly higher in cADR patients than in tolerant controls (58.0% versus 5.9%, p = 8.2 9 10E-5, pc = 1.1 9 10E-3) and the Han Chinese population (58.0% versus 15.5%, p = 1.2 9 10E-4, pc = 1.7 9 10E-3), respectively. In addition, the present drug-protein moulding data revealed that clarithromycin could bind to and interact with HLA-A*02:07 in three binding possibilities. The present study suggests that HLA-A*02:07 is a genetic risk factor in the development of clarithromycin-induced cADRs in the Han Chinese population. The prevalence of cADRs depends on the gender, age, health condition and genetic background of patients, as well as other aspects, such as genetics [14] . For example, previous studies did show that genetic variability significantly contributed to severe allergic reactions [9] [10] [11] . Furthermore, the HLA complex might play a key role in allergic cutaneous reactions [10, 11] . Among these, MHC proteins coded by HLA class I are localized on the cell surface as a part of the immune system, which presents short endogenous or exogenous polypeptides to T lymphocytes and induces and produces acquired allergic reactions after drug administration [10, 11] . In this regard, HLA could be important for mediating the human body's defence against bacterial or viral infections. However, HLA also plays an important role in the rejection of organ transplantation and drug allergic reactions [12, 13] . In the present study, it was found that HLA-A*02:07 was significantly associated with clarithromycin-cADRs and that it may serve as a potential genetic marker to predict risk in the development of clarithromycin-cADRs in Chinese Han patients. Moreover, previous studies have shown that HLA-A*31:01 and HLA-B*15:02 were also the specific genetic determinants in carbamazepine-induced cADRs, such as epidermal necrolysis, maculopapular exanthema (MPE) or Stevens-Johnson syndrome (SJS) [15] [16] [17] [18] [19] [20] [21] . Specifically, Moon et al. [19] reported a significant association between the HLA-A*24:02 allele and lamotrigine-induced MPE in lamotrigine-tolerant Koreans and the general Korean population. HLA-A*02:01 has been shown to be a biomarker for lamotrigine-induced MPE, while HLA-A*01:01 and HLA-A*31:01 are candidate alleles for their association with carbamazepine-induced MPE [20] . Furthermore, HLA-A*02:01, HLA-A*02:06 and HLA-A*02:07 alleles have been observed to be associated with tetanus antitoxin-induced exanthematous drug eruptions in the Han Chinese population [21] , while the screening of the HLA-B*57:01 allele before initiating abacavir therapy has been highly recommended to prevent abacavir-induced hypersensitivity reactions [22, 23] . Taken together, these studies clearly indicate that HLA plays an important role in the development of various cADRs. However, it is well known that there is a relatively strong linkage disequilibrium between A*02:07 and B*46:01 in Chinese and other East Asian populations (see allelefrequencies.net), and it is possible that this is the reason why both alleles appeared to be associated in the present case and control analysis, even though B*46:01 appeared to have no association when the larger control group was used in the present study. Thus, future studies with multiple populations and a larger sample size are needed to validate the present data.
However, to date, it remains unclear how clarithromycin interacts with HLA-A*02:07 in cADR development. Hence, in the present study, their molecular interactions were assessed using three models of the HLA-A*02:07-clarithromycin complexes with the Glide module of Maestro version 9.0. It was found that clarithromycin could bind to and interact with HLA-A*02:07 in two HLA-A sites and in the interface of HLA-A and b 2 -microglobulin with low energy and low docking scores. The molecular docking model of the HLA-A*02:07-clarithromycin complex in the HLA-A site had a docking score of À6.2 and revealed three hydrogen bonds of the hydroxyl group of clarithromycin directly linked to the hydroxyl groups of Thr 163, Glu 63 and Arg 97 in the HLA-A*02:07 protein, while the molecular docking model of the HLA-A*02:07-clarithromycin complex in the interface of HLA-A and b 2 -microglobulin had a docking score of À6.5 and had three hydrogen bonds of the hydroxyl group of clarithromycin directly linked to the hydroxyl groups of Asp 30, Arg 6 and Ser 2 in the HLA-A*02:07 protein. Similar to previous studies, the HLA-A site could be responsible for the main function of HLAs [24, 25] , although the exact binding pose of the HLA-A*02:07-clarithromycin complex may need to be further confirmed in future studies. Similarly, such molecular moulding of interactions between clarithromycin and other HLA subtypes such as HLA-A*02:01 had similar data, because HLA-A*02:01 C123Y SNP is far from the binding sites of clarithromycin.
However, the present study does have several limitations. For example, the sample size was small, which could contribute to potential limitations in statistical power. Although some ADRs are associated with large-effect genetic risk factors that could be identified using a small number of samples, further studies are needed to verify the present data. Moreover, the clarithromycin dosage used for each patient was not specifically disclosed or consistent, although it has been considered that allergic reactions may not associate with drug dose, except for allopurinol. In conclusion, the present study demonstrates that HLA-A*02:07 is a risk factor in developing clarithromycin-induced drug allergies in the Chinese Han population. Thus, the genotyping of HLA-A*02:07 may help physicians predict cADRs before the initiation of clarithromycin therapy to patients. Furthermore, the precise prediction of cADRs and treatments with alternative antibiotics could be the key solution to reduce cADRs.
